Quantcast

Latest Thrombophilia Stories

2014-06-16 04:21:39

IMPACT Dx(TM) Combined Function System Will Also Be Available in the European Union SAN DIEGO, June 16, 2014 /PRNewswire/ -- Agena Bioscience, Inc., which recently acquired the Bioscience business of Sequenom, Inc., was notified today by Sequenom, Inc. that it received premarket clearance from the U.S. Food and Drug Administration (FDA) for the IMPACT Dx(TM) Factor V Leiden and Factor II Genotyping Test and the IMPACT Dx(TM) System. The IMPACT Dx(TM) Factor V Leiden and Factor II...

2012-01-09 14:31:15

A Rush University Medical Center led international research team has announced that a treatment to prevent bleeding episodes in children with hemophilia A also is effective for adolescents and adults. The preventive therapy will “optimize care for hemophilia patients of all ages by stopping unexpected bleeding events that can have a detrimental impact on the lives of patients,” said Dr. Leonard Valentino, director of the Rush Hemophilia and Thrombophilia Center and principal...

2011-06-06 19:39:49

Back in the mid 19th century, a French doctor, Armand Trousseau, discovered a connection between cancer and thrombosis "“ the formation of often dangerous blood clots that can lead to venous occlusion. Today it is known that cancer and its treatment change blood flow properties and thus promote the formation of clots. However, clots do not only occur as a side effect and consequence of cancer, but, vice versa, an increased blood clotting tendency may also be associated with an elevated...

2010-09-14 09:33:00

Arming Healthcare Professionals to Stop the Clot® TARRYTOWN, N.Y., Sept. 14 /PRNewswire-USNewswire/ -- The National Blood Clot Alliance (NBCA) is making available an easily accessible, no-cost online curriculum for nurses, nurse practitioners, physician assistants, and pharmacists to help increase understanding about the diagnosis and treatment of blood clots and blood clotting disorders. Access to the curriculum, entitled Stop The Clot®: What Every...

2010-08-02 09:00:00

CHICAGO and HOBOKEN, N.J., Aug. 2 /PRNewswire/ -- Octapharma USA today announced the first grant recipient of the Octapharma 25th Anniversary Grants Program is the Rush Hemophilia & Thrombophilia Center at Rush University Medical Center. The Octapharma grants program supports clinical or pre-clinical research focused on human protein therapies in hematology, immune therapy, intensive care and emergency medicine. Leonard A. Valentino, M.D., Director of the Section of Pediatric...

2009-06-16 15:00:00

ROCKVILLE, Md., June 16 /PRNewswire-USNewswire/ -- According to a new report by HHS' Agency for Healthcare Research and Quality, there is insufficient evidence to conclude that genetic testing for two gene mutations in adults with a history of blood clots helps to prevent a condition known as deep-vein thrombosis or to improve other clinical outcomes. The report, a summary of which will be published in the June 17 issue of JAMA, also failed to find any benefit from genetic testing of family...

2009-06-03 06:00:00

On-Demand Test for Genetic Risk of Thrombosis Improves Time-to-Result over Current Molecular Tests SUNNYVALE, Calif. and BEDFORD, Mass., June 3 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD) and Instrumentation Laboratory today announced that Health Canada has issued Cepheid a medical device license for its Xpert HemosIL FII & FV test. The test detects Factor II (FII) and Factor V Leiden (FV) genetic variations associated with thrombophilia, an increased risk of blood clots...

2009-05-04 07:30:00

- Court Orders Confiscation of Diagnostica Stago's Inventory of Infringing Products - BEDFORD, Mass., May 4 /PRNewswire/ -- Instrumentation Laboratory Company and its parent company Instrumentation Laboratory S.p.A. (IL) today announced that the Paris First Level Civil Court determined that Diagnostica Stago infringed the French counterparts of two European patents licensed exclusively to IL, and committed acts of unfair competition due to denigrating advertisements. As a result, the Court...

2008-10-30 09:00:40

SeraCare Life Sciences, Inc. (NASDAQ: SRLS) launched the Company's anticipated genetic controls business with the introduction of two new products at the Association for Molecular Pathology 2008 Annual Meeting. Initial products launched include ACCURUN(R) 601 controls for diagnostic testing of warfarin sensitivity and ACCURUN(R) 610 controls for thrombophilia testing, which were developed internally by SeraCare. Additionally, the Company announced that it has entered into an exclusive...

2008-02-28 03:00:09

By Poredos, P Jezovnik, M K During the last decade, the role of inflammation in the etiopathogenesis of arterial thrombosis has been elucidated. However, little is known about the relationship between inflammation and venous thrombosis. Recently, inflammation has been accepted as a possible mechanism through which different risk factors trigger thrombus formation in veins. The data indicate that inflammation of the vessel wall initiates thrombus formation in an intact vein and that...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related